Planned sales, announced before they happen
7 trading plans running, 23 Form 144 notices for $62.6M
Plans running now
7
Andrew J. Murphy, Ph.D, Michael S. Brown, M.D., Marion McCourt, Kathryn Guarini, Ph.D., Joseph L. Goldstein, M.D., Huda Y. Zoghbi, M.D., Arthur F. Ryan
What REGN's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Trading plans
Plans adopted or ended
| Insider | What | Date | Shares | Runs to | Reported in |
|---|---|---|---|---|---|
| Andrew J. Murphy, Ph.D Executive Vice President, Co-Chief Scientific Officer |
Adopted 10b5-1 plan | May 7, 2026 | up to 84,000 | Dec 31, 2027 | 10-Q Jul 30, 2026 |
| Michael S. Brown, M.D. Director |
Adopted 10b5-1 plan | Feb 25, 2026 | up to 1,929 | Dec 30, 2026 | 10-Q Apr 29, 2026 |
| Marion McCourt Executive Vice President, Commercial |
Adopted 10b5-1 plan | Feb 17, 2026 | up to 6,989 | May 5, 2027 | 10-Q Apr 29, 2026 |
| Kathryn Guarini, Ph.D. Director |
Adopted 10b5-1 plan | Feb 13, 2026 | up to 1,600 | Feb 5, 2027 | 10-Q Apr 29, 2026 |
| Joseph L. Goldstein, M.D. Director |
Adopted 10b5-1 plan | Feb 5, 2026 | up to 1,929 | Nov 30, 2026 | 10-Q Apr 29, 2026 |
| Huda Y. Zoghbi, M.D. Director |
Adopted 10b5-1 plan | Nov 20, 2025 | up to 2,438 | Jan 3, 2027 | 10-K Feb 4, 2026 |
| Jason Pitofsky Senior Vice President, Controller |
Adopted 10b5-1 plan | Nov 10, 2025 | up to 3,261 | May 10, 2026 | 10-K Feb 4, 2026 |
| Arthur F. Ryan Director |
Adopted 10b5-1 plan | Oct 31, 2025 | up to 1,200 | Jan 29, 2027 | 10-K Feb 4, 2026 |
| Bonnie L. Bassler, Ph.D. Director |
Adopted 10b5-1 plan | May 2, 2025 | up to 5,121 | May 1, 2026 | 10-Q Aug 1, 2025 |
| Joseph L. Goldstein, M.D. Director |
Adopted 10b5-1 plan | Feb 13, 2025 | up to 1,929 | Nov 30, 2025 | 10-Q Apr 29, 2025 |
| Kathryn Guarini, Ph.D. Director |
Adopted 10b5-1 plan | Nov 1, 2024 | up to 1,000 | Nov 14, 2025 | 10-K Feb 5, 2025 |
| Jason Pitofsky Vice President, Controller |
Adopted 10b5-1 plan | Aug 7, 2024 | up to 3,791 | May 10, 2025 | 10-Q Oct 31, 2024 |
| Joseph L. Goldstein, M.D. Director |
Adopted 10b5-1 plan | Aug 7, 2024 | up to 1,929 | Feb 7, 2025 | 10-Q Oct 31, 2024 |
| Arthur F. Ryan Director |
Adopted 10b5-1 plan | Aug 3, 2024 | up to 1,200 | Oct 31, 2025 | 10-Q Oct 31, 2024 |
| Bonnie L. Bassler, Ph.D. Director |
Adopted 10b5-1 plan | Feb 27, 2024 | up to 3,851 | 428 days | 10-Q May 2, 2024 |
| Michael S. Brown, M.D. Director |
Adopted 10b5-1 plan | Feb 26, 2024 | up to 2,707 | 187 days | 10-Q May 2, 2024 |
| Joseph J. LaRosa Executive Vice President, General Counsel and Secretary |
Adopted 10b5-1 plan | Feb 16, 2024 | up to 5,191 | 360 days | 10-Q May 2, 2024 |
| George D. Yancopoulos, M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer |
Adopted 10b5-1 plan | Feb 14, 2024 | up to 100,000 | 362 days | 10-Q May 2, 2024 |
| Marion McCourt Executive Vice President, Commercial |
Adopted 10b5-1 plan | Feb 13, 2024 | up to 8,122 | 473 days | 10-Q May 2, 2024 |
| Leonard S. Schleifer, M.D., Ph.D. Board co-Chair, President and Chief Executive Officer |
Adopted 10b5-1 plan | Feb 5, 2024 | up to 229,204 | 547 days | 10-Q May 2, 2024 |
| Robert E. Landry Executive Vice President, Finance and Chief Financial Officer |
Adopted 10b5-1 plan | Nov 9, 2023 | up to 14,337 | 179 days | 10-K Feb 5, 2024 |
| Christopher Fenimore Senior Vice President, Controller |
Adopted 10b5-1 plan | Aug 25, 2023 | up to 8,940 | 174 days | 10-Q Nov 2, 2023 |
| Joseph L. Goldstein, M.D. Director |
Adopted 10b5-1 plan | Aug 24, 2023 | up to 3,537 | 274 days | 10-Q Nov 2, 2023 |
| Michael S. Brown, M.D. Director |
Adopted 10b5-1 plan | Aug 24, 2023 | up to 2,049 | 274 days | 10-Q Nov 2, 2023 |
| Arthur F. Ryan Director |
Adopted 10b5-1 plan | Aug 7, 2023 | up to 1,200 | 480 days | 10-Q Nov 2, 2023 |
| Bonnie L. Bassler, Ph.D. Director |
Adopted 10b5-1 plan | May 11, 2023 | up to 3,969 | 447 days | 10-Q Aug 3, 2023 |
| Andrew J. Murphy, Ph.D. Executive Vice President, Research |
Adopted 10b5-1 plan | May 9, 2023 | up to 80,000 | 602 days | 10-Q Aug 3, 2023 |
| Huda Y. Zoghbi, M.D. Director |
Adopted 10b5-1 plan | May 5, 2023 | up to 2,117 | 281 days | 10-Q Aug 3, 2023 |
Show the other 20 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 4, 2023.
Form 144
Notices of planned sales
| Filed | Seller | Shares | Value | Shares came from | 10b5-1 plan | Form 4 sales after |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | Jason Pitofsky Officer |
3,883 | $3.8M | stock option grant | none given | 4,062 shares from Nov 4, 2026 |
| Nov 4, 2026 | Jason Pitofsky Officer |
180 | $175K | Inherited | none given | 4,062 shares from Nov 4, 2026 |
| Nov 3, 2026 | Huda Zoghbi Director |
7,439 | $7.2M | stock option exercise | none given | 7,439 shares from Nov 3, 2026 |
| Nov 2, 2026 | Joseph LaRosa Officer |
4,466 | $4.3M | Stock Option Exercise | none given | 4,466 shares from Nov 2, 2026 |
| Nov 2, 2026 | Christine Poon Director |
7,830 | $7.5M | Acquired as compensation -- Stock Options | none given | 7,830 shares from Nov 2, 2026 |
| Nov 2, 2026 | GEORGE L. SING Director |
21,129 | $20.4M | Exercise of Options Under a Registered Plan; Previously Exercised Options | none given | 21,129 shares from Nov 2, 2026 |
| Oct 30, 2026 | Guarini Kathryn Director |
400 | $360K | Exercise of stock option | adopted Feb 13, 2026 | 400 shares from Oct 30, 2026 |
| Oct 30, 2026 | McCourt Marion Officer |
1,132 | $984K | RSA Vesting | adopted Feb 17, 2026 | 1,132 shares from Oct 30, 2026 |
| Oct 30, 2026 | MICHAEL S BROWN Director |
1,929 | $1.6M | Exercise of Stock Options | adopted Feb 25, 2026 | 1,929 shares from Oct 30, 2026 |
| Oct 14, 2026 | MURPHY ANDREW J Officer |
4,147 | $3.2M | Exercise of Stock Options | adopted May 7, 2026 | 4,147 shares from Oct 14, 2026 |
| Sep 3, 2026 | McCourt Marion Officer |
1,131 | $969K | RSA Vesting | adopted Feb 17, 2026 | 1,131 shares from Sep 3, 2026 |
| Sep 2, 2026 | McCourt Marion Officer |
1,215 | $1.0M | RSA Vesting | adopted Feb 17, 2026 | 2,346 shares from Sep 2, 2026 |
| Sep 2, 2026 | Guarini Kathryn Director |
400 | $340K | Exercise of stock option | adopted Feb 13, 2026 | 400 shares from Sep 2, 2026 |
| Aug 10, 2026 | Zoghbi Huda Y Director |
800 | $640K | Exercise of stock options | adopted Nov 20, 2025 | 800 shares from Aug 10, 2026 |
| Aug 10, 2026 | Guarini Kathryn Board member |
400 | $320K | Exercise of stock option | adopted Feb 13, 2026 | 800 shares from Aug 10, 2026 |
| Jul 2, 2026 | Arthur F. Ryan Director |
400 | $250K | Compensation | adopted Oct 31, 2025 | 200 shares from Jul 2, 2026 |
| Feb 19, 2026 | Zoghbi Huda Y Director |
1,638 | $1.3M | Exercise of stock options | adopted Nov 20, 2025 | none found |
| Feb 9, 2026 | Pitofsky Jason Officer |
2,036 | $1.6M | Exercise of Stock Options; Restricted Stock Award | adopted Nov 10, 2025 | none found |
| Feb 9, 2026 | Arthur F. Ryan Director |
400 | $314K | Compensation | adopted Oct 31, 2025 | none found |
| Jan 7, 2026 | Bassler Bonnie L Director |
1,500 | $1.2M | OPTION EXERCISE | adopted May 2, 2025 | none found |
| Nov 20, 2025 | Bassler Bonnie L Director |
760 | $570K | OPTION EXERCISE | adopted May 2, 2025 | none found |
| Nov 7, 2025 | Jason Pitofsky Officer |
431 | $281K | Restricted Stock Award | none given | none found |
| Oct 29, 2025 | Christine Poon Director |
6,500 | $4.2M | Acquired as compensation -- Stock Options | none given | none found |
Show the other 15 notices
From the Form 144 XML filed with the SEC, since Oct 29, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.